Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$65.34 USD

65.34
734,584

+0.54 (0.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 101 - 120 ( 304 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 101

12/05/2018

Daily Note

Pages: 6

Innovation Drives Expected Clinical Pipeline Expansion

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 102

11/27/2018

Daily Note

Pages: 6

Reldesemtiv Hopefully to Show FORTITUDE; Enrollment Completed

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 103

11/02/2018

Company Report

Pages: 7

3Q18 Results; Programs Continue Expansion With Drive Toward Meaningful Inflection Points

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 104

10/17/2018

Company Report

Pages: 13

Flexing Pipeline Muscles at R-D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 105

10/05/2018

Company Report

Pages: 6

Couple of Interim Setbacks to Reldesemtiv Program; Omecamtiv Drives Lion''s Share of Valuation; Target Adjusted to $21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 106

07/27/2018

Company Report

Pages: 6

2Q18 Results; Discussions Revving Up for SMA Next Steps; Bring on the FDA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 107

06/18/2018

Company Report

Pages: 12

For a Hypothesis Generating Study, We Sure Are Impressed With Reldesemtiv; Target Increased to $24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 108

04/27/2018

Company Report

Pages: 6

1Q18 Results; Flow of Clinical Data Starting in June for Reldesemtiv in SMA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 109

02/16/2018

Company Report

Pages: 6

2017 Results; Anticipation Mounting for Reldesemtiv Data Readouts

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 110

01/19/2018

Company Report

Pages: 6

The Year of CK-107; That Blood Brain-Barrier Is Our Friend; Target Increased to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 111

11/21/2017

Company Report

Pages: 5

Tirasemtiv out as Focus Shifts to CK-107 and Then Omecamtiv Longer Term; Target Reduced to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 112

10/27/2017

Company Report

Pages: 6

3Q17 Results; Interesting Times They''re a Comin''

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 113

09/20/2017

Company Report

Pages: 5

More Milestone Cash and VITALITY-ALS Data Around the Corner

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 114

08/03/2017

Company Report

Pages: 6

2Q17 Results; Busy Bees as We Approach Pivotal Tirasemtiv Data; PT up to $26

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 115

08/03/2017

Company Report

Pages: 6

2Q17 Results; Busy Bees as We Approach Pivotal Tirasemtiv Data; PT up to $26

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 116

05/25/2017

Company Report

Pages: 4

We are dropping coverage of CYTK shares to reallocate our research resources

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 117

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 118

04/28/2017

Company Report

Pages: 6

1Q17 Results; The Excitement Is Palpable; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 119

04/28/2017

Company Report

Pages: 6

1Q17 Results; The Excitement Is Palpable; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 120

04/25/2017

Daily Note

Pages: 7

Early Looking Glass Into SMA Demand as We Remind About Upcoming CK-107 First Look; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party